Puma Biotech Q2 net income $8.2M, raises 2026 guidance on NERLYNX demand

PUMA BIOTECHNOLOGY, INC.

Q2 product revenue $53.6M (+9% YoY); GAAP net income $8.2M ($0.16/sh) vs $5.9M ($0.12/sh) in Q2 2025.
Non-GAAP adjusted net income $10.1M ($0.20/sh basic) vs $7.5M ($0.15/sh) prior year.
Raises FY 2026 net product revenue guidance to $205-209M (prior $202-206M); net income to $17-20M (prior $16-19M).
Debt fully repaid in May 2026; cash & securities $93.9M at June 30, 2026.
R&D expenses rose $9.4M YTD on alisertib trial activity; milestones include ALISCA-Lung2 initiation in Q3 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.